Open AccessEvaluation of Posttransplant Methotrexate to Facilitate Engraftment in the Canine Major Histocompatibility Complex-Haploidentical Nonmyeloablative Transplant Model
Author(s) -
Monica S. Thakar,
Erlinda B. Santos,
Theodore A. Gooley,
George E. Sale,
Rainer Storb,
Hans Peter Kiem,
Brenda M. Sandmaier
Publication year - 2010
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181e0a0c4
Subject(s) - methotrexate , histocompatibility , major histocompatibility complex , medicine , immunology , histocompatibility testing , immune system , antigen , human leukocyte antigen
Posttransplant cyclophosphamide has been shown to control graft-versus-host disease and facilitate engraftment in the major histocompatibility complex-haploidentical transplant setting. Here, we hypothesized that methotrexate (MTX) could be used in a similar fashion. In patients with genetic diseases, the use of MTX rather than an alkylating agent such as cyclophosphamide would be preferable due to its reduced risk of promoting secondary malignancies.